drug_type
RELEVANT_DRUG
intervention_type
Biologic (bispecific antibody; T-cell engager)
drug_description
An intravenous BCMA x CD3 bispecific T-cell–engaging antibody that binds BCMA (TNFRSF17) on multiple myeloma plasma cells and CD3 on T cells to form an immune synapse, activate TCR/CD3 signaling, and redirect T cells to lyse BCMA-positive tumor cells via perforin/granzyme release and cytokine-driven cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibodies, Bispecific
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
Intravenous BCMA×CD3 bispecific antibody that binds BCMA on multiple myeloma cells and CD3 on T cells to form an immune synapse, activate TCR/CD3 signaling, and redirect T cells to kill BCMA-positive tumor cells via perforin/granzyme release and cytokine-mediated cytotoxicity.
drug_name
YKST02
nct_id_drug_ref
NCT06574568